12 search results for: IL-4
Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?
Dr. Amy Paller discusses how targeting IL-4 and IL-13 can improve burden of AD.
What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?
Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.
IL-4 Contributes to Systemic Type 2 Inflammation in AD
In this highlight video from the ADVENT AD symposium held at EADV’s 2024 Annual Meeting in Amsterdam, Dr. Stephan Weidinger discusses how IL-4 contributes to systemic type 2 inflammation in AD via several mechanisms, including T cell differentiation, B cell activation and IgE generation, and T regulatory cell inhibition.
IL-4 Is the Primary Cytokine That Drives Th2 Cell Polarization and Amplifies Type 2 Inflammation
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof Oscar Palomares describes how IL-4 is the key cytokine involved in the initiation and perpetuation of Th2 cell responses and type 2 inflammation.
Itch in Chronic Inflammatory Skin Diseases: Histaminergic and Nonhistaminergic Mechanisms and Role of IL-4 as a Central Orchestrator in Promoting Neuronal Sensitization
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Brian Kim explores the histaminergic and nonhistaminergic mechanisms of itch, highlighting how type 2 cytokines like IL-4 serve as central orchestrators of neuronal sensitization and immune–nervous system cross-talk.
Barrier disruption in AD and the development of environmental and food allergies
Dr. Casale discusses the critical role of barrier disruption in atopic dermatitis
Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone
Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation
KOL Video Interview – Dr Amy Paller
In this exclusive video interview, Dr Amy Paller discusses two topics: 1) The importance of CCL17 (TARC) as a biomarker in pediatric patients with AD, and 2) How IL-4 and IL-13 contribute to skin barrier dysfunction in AD.
World Congress of Dermatology (WCD) 2023 | Singapore
Highlights from the ADVENT symposium at the 2023 World Congress of Dermatology in Singapore.
Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma
Join Dr. Celeste Porsbjerg as she discussed on how type 2 inflammation may lead to airway remodeling in asthma, exploring the pathophysiologic mechanisms, that ultimately lead to structural changes and irreversible loss of lung function
Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis
Learn more about how chronic and systemic type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis
